About
Company Overview
Company Name | Vision Care Inc. |
---|---|
Representative | Masayo Takahashi, President and Representative Director |
Location | Kobe Eye Center 5F, 2-1-8 Minatojima-minamimachi, Chuo-ku, Kobe 650-0047, Japan |
Established | March 10, 2017 |
Capital | 20 million yen |
Fiscal year end | End of February |
Business | Purpose Management of subsidiaries Research and development in the fields of ophthalmology and regenerative medicine Consulting in the fields of ophthalmology and regenerative medicine Employment support and lifestyle support for low vision people |
Subsidiary company | VCGT Inc. VCCT Inc. |
---|
Members
President and CEO
Masayo Takahashi MD, PhD
Affiliations:
- Councilor, Japan Ophthalmological Society
- Executive Director, Japan Society for Regenerative Medicine
- Executive Director, Japan Retina and Vitreous Society
- Director, Japan Retinitis Pigmentosa Society
- Director, Public Interest Incorporated Foundation NEXT VISION
- Fellow, Ritsumeikan Advanced Research Academy (RARA), Ritsumeikan University
- Senior Adviser, Research Center, Kobe City Eye Hospital Membership in International Organizations
- The Association for Research in Vision and Ophthalmology (ARVO)
- Academia Ophthalmologica Internationalis (AOI)
- International Member, National Academy of Medicine (NAM)
- Associate Member, European Molecular Biology Organization (EMBO)
Masayo Takahashi is an ophthalmologist who completed her doctoral program (Visual Pathology) at the Graduate School of Medicine, Kyoto University. She served as the leader of the Laboratory for Retinal Regeneration, RIKEN Center for Biosystems Dynamics Research from 2006 to 2022, conducting groundbreaking clinical research using the world’s first induced pluripotent stem (iPS) cells in 2014. In 2017, she collaborated with the city of Kobe to establish the “Kobe Eye Center.” After leaving RIKEN in 2019, she became the CEO of Vision Care Inc. and subsequently founded two subsidiary companies dedicated to gene therapy development and cell therapy research.
Director and COO
Keita Okuda
Keita Okuda graduated from the Faculty of Law at Kyoto University and went on to establish Value Create Inc. after working at MUFG Bank, Ltd. He assumed the role of Representative Director. Engaging in a diverse range of corporate development, revitalization, and management endeavors, he is involved in both for-profit and non-profit sectors. He has contributed greatly to the establishment of Vision Care Inc. and Kobe Eye Center.
Director and CFO
Takuma Fukuda
After graduating from the Faculty of Education at Waseda University, Takuma Fukuda worked at Daiwa Securities Co. Ltd. before founding BuzzBox Inc. engaged in recruitment support services, which he later sold. He has since focused on investment and business development in the healthcare and human resources sectors. Leveraging his diverse experiences, he is actively involved in the management of the Vision Care Group as a founding member.
Outside Director
Kazuhiko Toyama
Kazuhiko Toyama, a graduate of the Faculty of the University of Tokyo and holds an MBA from Stanford University. He has passed the Japanese National Bar Examination. He worked at Boston Consulting and Corporate Directions before becoming the COO of the Industrial Revitalization Corporation of Japan, where he engaged in the revitalization of over 40 companies, including Mitsui Mining and Kanebo. He has been involved in the management reform and growth support of numerous companies and has held positions such as Chairman of IGPI Group, Industrial Growth Platform, Inc. (IGPI) and External Director of Panasonic.
Executive Advisor
Kanoko Oishi
Kanoko Oishi, a graduate of the Faculty of Law at Osaka University, obtained an MBA from Harvard Business School. After serving as a partner at McKinsey & Company, she founded Mediva Inc. with the aim of transforming Japan’s medical and caregiving fields from the perspective of patients and users. She focuses on business development, operations, and consulting. She has held positions such as committee member for the Cabinet Office (Council for Regulatory Reform), the Ministry of Health, Labour and Welfare, and the Ministry of Economy, Trade and Industry. She also serves as a Japan Advisory Board Member for Harvard Business School and a committee member of the Osaka University Management Council.
Executive Advisor
Yasunori Kaneko
Yasunori Kaneko, a graduate of the School of Medicine at Keio University, obtained a Master of Business Administration (MBA) from Stanford University. He is known for his pioneering work in the field of biotechnology, having worked at Genentech, Inc. a leading bioventure. He held various positions including Senior Vice President and CFO at Ionis Pharmaceuticals Inc. , and Vice President of Business Development and CFO at Tularik, Inc. In 1999, he became involved in the founding of the venture capital firm Skyline Ventures, where he served as Managing Director. Currently, he is the Lead Independent Director of Arcus Biosciences,Inc., and an External Director at ProvigateProvigate,Inc.
Access
Transportation and Access Information
By train
2 minutes walk from “Iryo Center” station of Portliner.
From Sannomiya
Please take the train bound for Kobe Airport. Please note that the bus bound for “North Pier” does not stop at this station.
From Kobe Airport
Please take the Port Liner through the connecting passageway from the 2nd floor of the Airport Terminal Building. All trains stop in front of the hospital.
By car
Follow signs for Port Island from all directions. It takes about 15 minutes after crossing Kobe Ohashi.
You can also use Minatojima Tunnel in Sannomiya East.
Using Hanshin Expressway Route 3
Exit at “Ikuta River IC” or “Kyobashi IC” and follow the signs for Port Island.
Using Hanshin Expressway Wangan Route 5
Exit at “Sumiyoshigawa IC” and proceed via “Harbor Highway” and follow the signs for Port Island.
Parking lot
Parking is available at the Advanced Medical Center and Kobe Eye Center. Parking for general use is available 24 hours a day. Fee: 160 yen per hour (daily limit is 1,000 yen).
*1-3 hours may be free depending on the nature of use.